Verona Pharma plc

NasdaqGM:VRNA Stock Report

Market Cap: US$9.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Verona Pharma Future Growth

Future criteria checks 5/6

Verona Pharma is forecast to grow earnings and revenue by 56.6% and 39.7% per annum respectively while EPS is expected to grow by 57% per annum.

Key information

56.6%

Earnings growth rate

57.04%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate39.7%
Future return on equityn/a
Analyst coverage

Good

Last updated06 Aug 2025

Recent future growth updates

Analysts Are Upgrading Verona Pharma plc (NASDAQ:VRNA) After Its Latest Results

Mar 02
Analysts Are Upgrading Verona Pharma plc (NASDAQ:VRNA) After Its Latest Results

Recent updates

Verona Pharma: An Impressive Initial Launch

Jun 18
User avatar

Ohtuvayre Launch And EU Approval Will Unlock Future Markets

Rapid adoption of Ohtuvayre for COPD and strong prescription growth suggest significant future revenue potential.

This Just In: Analysts Are Boosting Their Verona Pharma plc (NASDAQ:VRNA) Outlook for This Year

May 01
This Just In: Analysts Are Boosting Their Verona Pharma plc (NASDAQ:VRNA) Outlook for This Year

Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?

Apr 12
Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?

Verona Pharma: Great Year For Share Price, But Competition Threatens Bull Thesis

Mar 13

New Forecasts: Here's What Analysts Think The Future Holds For Verona Pharma plc (NASDAQ:VRNA)

Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Verona Pharma plc (NASDAQ:VRNA)

Analysts Are Upgrading Verona Pharma plc (NASDAQ:VRNA) After Its Latest Results

Mar 02
Analysts Are Upgrading Verona Pharma plc (NASDAQ:VRNA) After Its Latest Results

Verona Pharma's Ohtuvayre Defies Expectations In Q4, But Stock Alpha May Now Be Limited

Jan 08

Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?

Jan 07
Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?

Verona Pharma: In COPD, There's A Corner With Their Name On It

Nov 27

Verona Pharma: A Post FDA Approval Analysis

Sep 10

Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst

Jun 20

Verona Pharma: Key Inflection Point Directly Ahead

May 23

Verona Pharma: A Few Points From The Bull And Bear Case

Feb 15

Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data

Jan 19

Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point

Sep 13

Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials

Aug 19

Verona Pharma GAAP EPS of -$0.04 beats by $0.23

Aug 09

Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster

Feb 04

Earnings and Revenue Growth Forecasts

NasdaqGM:VRNA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,143484461N/A6
12/31/202673023622414610
12/31/2025395146215
6/30/2025222-81-74-72N/A
3/31/2025119-164-121-120N/A
12/31/202442-173-123-122N/A
9/30/20246-154-104-104N/A
6/30/2024N/A-125-54-54N/A
3/31/2024N/A-63-58-58N/A
12/31/2023N/A-54-50-50N/A
9/30/20230-51-48-48N/A
6/30/20230-52-53-53N/A
3/31/20230-61-51-51N/A
12/31/20220-69-60-60N/A
9/30/2022N/A-82-69-69N/A
6/30/202240-55-29-29N/A
3/31/202240-59-29-29N/A
12/31/202140-56-33-33N/A
9/30/202140-57-35-35N/A
6/30/2021N/A-87-68-68N/A
3/31/2021N/A-74-50-50N/A
12/31/2020N/A-65-45-45N/A
9/30/2020N/A-50-38-38N/A
6/30/2020N/A-43N/AN/AN/A
3/31/2020N/A-46-44-44N/A
12/31/2019N/A-41-43-43N/A
9/30/2019N/A-35-38-38N/A
6/30/2019N/A-25N/AN/AN/A
3/31/2019N/A-13N/A-28N/A
12/31/2018N/A-25N/A-23N/A
9/30/2018N/A-30N/A-23N/A
6/30/2018N/A-40N/A-33N/A
3/31/2018N/A-47N/A-33N/A
12/31/2017N/A-28N/A-28N/A
9/30/2017N/A-20N/A-24N/A
6/30/2017N/A-11N/A-15N/A
3/31/2017N/A-8N/A-10N/A
12/31/2016N/A-6N/A-7N/A
9/30/2016N/A-8N/A-6N/A
6/30/2016N/A-7N/A-6N/A
3/31/2016N/A-9N/A-8N/A
12/31/2015N/A-11N/A-9N/A
9/30/2015N/A-10N/A-9N/A
6/30/2015N/A-8N/A-9N/A
3/31/2015N/A-6N/A-7N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VRNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).

Earnings vs Market: VRNA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: VRNA is expected to become profitable in the next 3 years.

Revenue vs Market: VRNA's revenue (39.7% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: VRNA's revenue (39.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VRNA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/06 13:56
End of Day Share Price 2025/10/06 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Verona Pharma plc is covered by 7 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrick TrucchioBerenberg
Cosmin FilkerGBC AG
Martin HallHardman & Co.